
safetyREADY is a pre-configured, multi-tenant cloud deployment of Oracle Argus Safety delivered by Navitas Life Sciences as a packaged service with migration, integration, analytics, and intake accelerators, targeting mid-cap pharma, biotech, and generics manufacturers that want Argus capability without running the implementation themselves.
Navitas Life Sciences' pharmacovigilance software offering is branded safetyREADY®, not "Navitas Vigilance." It is not a standalone PV platform: a packaged accelerator, configuration library, and managed-cloud wrapper for Oracle Argus Safety, whose case-processing engine remains Oracle's. Navitas markets itself as an Oracle Gold Partner that delivers Argus on a "pre-configured and pre-validated" multi-tenant cloud, with migration, integration, analytics, and intake accelerators built around it.
Sub-modules named by vendor: safetyREADY® Cloud (single-tenant and multi-tenant Argus hosting), safetyREADY® Migrate (legacy-to-Argus data migration), safetyREADY® Integration (clinical, gateway, QMS connectors), safetyREADY® Analytics (operational + scientific dashboards), safetyREADY® INTAKE (SAE intake automation), safetyREADY® Mobility and Social Media (consumer-channel AE capture).
safetyREADY does not include a proprietary safety database: an engagement is functionally an Oracle Argus deployment delivered as a service by Navitas, with Navitas IP wrapped around Argus rather than replacing it.
Corporate context: Navitas Life Sciences is majority-owned by H.I.G. Capital (75% acquired 2021); the Indian-listed parent TAKE Solutions Limited retains 25% and has documented "going-concern" disclosures, repeated auditor resignations citing fee constraints, and zero promoter shareholding as of December 2025 — material for vendor-viability diligence.
safetyREADY is pharma/biotech/medical-device PV by definition; there is no separate consumer-health or non-life-sciences edition. (Note: an unrelated "Navitas Safety" EHS product from Gardner James LLP and a Honeywell "NAVITAS" airport software are unrelated entities.)
Deployment: cloud-hosted Oracle Argus Safety, single-tenant or multi-tenant per customer election. On-premise option not advertised. Underlying cloud provider is undisclosed in vendor materials; ZoomInfo lists Amazon EC2 in Navitas's tech stack, but this is a corporate datapoint, not a product datasheet. Cloud region and sovereign-cloud options are undisclosed.
Access: browser-based Argus client (inherited). Native mobile apps for AE consumer intake are described under safetyREADY Mobility; technical specs (iOS/Android versions, MDM compatibility) are not published. SSO (SAML, OIDC, AzureAD, Okta) is an Argus capability; safetyREADY does not publish independent SSO specs.
API maturity is undisclosed. The integration module describes connectors at a concept level but does not publish a REST/GraphQL API specification, OpenAPI document, rate-limit table, or SDK list. Data residency: no publicly stated EU/India/US GovCloud commitments specific to safetyREADY.
Data standards supported: E2B(R2), E2B(R3), MedDRA, WHODrug — inherited from Oracle Argus. HL7/FHIR support is not specifically claimed for safetyREADY.
No starting price, per-user fee, per-tenant fee, or per-case rate is published, and the pricing model itself is undisclosed. Enterprise quote only, with no public configurator. No published trial; demo by request through a contact form. Reported deal sizes are undisclosed. By analyst inference based on safetyREADY's positioning (mid-cap and biotech Argus customers with bundled services), a representative engagement is likely $200K+ annual for Argus licence pass-through, cloud hosting, and Navitas services, but this figure is not vendor-disclosed. Minimum commitments, setup fees, and validation-support fees are not publicly disclosed.
Typical timeline not specifically published for safetyREADY. Related Navitas products are positioned at 3–4 weeks (pharmaREADY regulatory submissions, smaller scope) and 8–12 weeks (Aviator clinical-data Oracle deployments). Realistic safetyREADY timelines for an Argus deployment of any operational complexity are most likely 3–6+ months consistent with Argus industry norms, but vendor has not published a benchmark.
Services included with the licence versus priced separately are undisclosed. The product is sold inside a services engagement, so the licence/implementation/validation/training split is not transparent. Vendor offers training to business users and admin users post-go-live with 24/7 application support.
Migration: safetyREADY Migrate is positioned as "source- and target-agnostic" with pre-built data mappings. Vendor explicitly named experience with Oracle Argus legacy data and "legacy safety applications." No public claim names a migrator for legacy data from other safety databases. A Navitas case study referenced "Implementing Oracle Argus to support AEs & Technical Product Complaints processing for a device manufacturer."
PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.
A quoted customer described "thoughtful, quiet leadership that somehow brought all the right people together," "very high level of expertise, excellent communications," and "skill in leading the team to implement client requirements so smoothly." (Dr. Peg Fletcher, MedAssessment, Inc.) Customer testimonials on a separate Navitas blog cite "true collaboration," "clear communication," "prompt updates," and a "30% reduction in operational costs" for a non-company-case quality-check process — though this is a PV-services testimonial, not specifically a safetyREADY product testimonial.
No independent negative-review corpus exists. Users report nothing on G2 or Capterra because safetyREADY has no presence there. The absence of independent review evidence is itself a negative for a buyer who requires peer-validation in shortlist diligence. All analyst recognitions are for services and operations, not for the safetyREADY software product. Material vendor-viability flag at parent (TAKE Solutions): going-concern qualification (July 2023), auditor resignations citing fee constraints (Oct 2025; successor 51-day tenure Feb–Mar 2026), Q2 FY26 zero-revenue continuing-operations, zero promoter shareholding (Dec 2025). H.I.G.-owned operating subsidiary mitigates but does not eliminate the overhang.
Share your experience with Navitas safetyREADY anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section